Navigation Links
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Date:3/25/2009

ompany's Board of Directors; and other risks and uncertainties more fully described in ADVENTRX's press releases and periodic filings with the Securities and Exchange Commission. ADVENTRX's public filings with the Securities and Exchange Commission are available at http://www.sec.gov.

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. ADVENTRX does not intend to update any forward-looking statement as set forth in this press release to reflect events or circumstances arising after the date on which it was made.

                                       [Tables to Follow]

                                  ADVENTRX Pharmaceuticals, Inc.
                                 (A Development Stage Enterprise)
                            Summary Consolidated Financial Information
                               (In 000s except for per share data)

    Consolidated Statement of
     Operations Data:
                                      Three months ended  Twelve months ended
                                          December 31,         December 31,
                                       2008       2007       2008       2007
                                    (unaudited) (unaudited)

    Revenues                             $-         $-       $500       $500

    Operating expenses:
      Research and development        4,849      3,887     17,922     15,934
      In-process research and
       development                        -          -          -          -
      Selling, general and
       administrative                 2,644      1,884      9,720      8,679
      Depreciation and amortization      37         48        168        198
        Total operating expenses      7,530      5,819     27,810     24,811

    Loss from operations             (7,530)    (5,819)   (27,310)   (24,311)
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. ADVENTRX Announces Further Cost-Cutting Measures
2. ADVENTRX Provides Update on Strategic Transaction Process
3. ADVENTRX Announces Further Cost-Cutting Measures
4. ADVENTRX Exploring Strategic Options
5. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
6. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
7. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
8. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
9. ADVENTRX Settles Dispute With Former Licensee
10. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
11. ADVENTRX Appoints Vice President of Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... YORK , April 30, 2015 The following ... Board of Directors of China Cord Blood Corp (NYSE: ... the special committee of the independent directors of China Cord ... low privatization offer of $6.40 per share from Golden Meditech ... at $6.40 per share would greatly benefit Golden Med and ...
(Date:4/30/2015)... April 30, 2015 - ... Biotechnology Company   Shire (LSE: SHP, ... three months to March 31, 2015. ... million +9% +13% Total revenues $1,488 million +11% +15% ... GAAP operating income from continuing operations $475 million +55% ...
(Date:4/30/2015)... (PRWEB) April 30, 2015 Clinovo ... 2015 PharmaSUG Annual Conference held in Orlando, FL ... Staffing Solutions along with Leslie Kolman, Manager of Staffing ... latest Clinovo news at Booth #17. , “We ... Conference again this year”, Says Trisha Heredia, Senior Director ...
(Date:4/29/2015)... , April 29, 2015   Doximity , the ... all US doctors as members, announced a new, instant ... "Apply Using Doximity." With one click, all US physicians ... curriculum vitae (CV) for an open job opportunity, and ... Eighty seven percent of physicians are open ...
Breaking Biology Technology:April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 29Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 2Clinovo Exhibits at the 2015 PharmaSUG Annual Conference on May 17-20th in Orlando, FL 3Doximity Offering Hospitals Easy, Efficient Physician Application Tool 2
... Pearl Therapeutics, Inc.,a biopharmaceutical company developing treatments ... Colin Reisner, MD, FCCP,FAAAAI to the position of ... Development and Medical Affairs, and Michael Golden,to the ... "We are delighted to welcome Colin and ...
... New Clinical Trial Sites Recently Initiated To Support Ongoing ... Trials-, ... Including Four Phase II Trials in Major Disease Indications-, -Revenues Plus Cash On-Hand ... Advance ...
... HONG KONG, Dec. 20 /Xinhua-PRNewswire-FirstCall/ -- China Technology,Development ... a,provider of clean and renewable energy products and ... announced that it has completed,another step in its ... resources on the principal business of solar energy., ...
Cached Biology Technology:Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs 2Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs 3Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 2Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 3Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 4Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008 5CTDC Announces the Disposal of Non-core Business 2
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. today ... (FIDO ® ) Alliance tm , an industry ... members commit to share technology and collaborate to ... are interoperable, more secure and private, and easier ... identity verification that protects sensitive user information and ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... time in a restful state akin to hibernation rather than ... in cells, new research suggests. And instead of being ... restful period appears to be a programmed step for RNA ... cell division and decide where proteins will work in a ...
... Leuven scientists (VIB/KU Leuven) are using zebrafish as a model ... the mechanism of amyotrophic lateral sclerosis (ALS). As a result, ... for a future ALS treatment. ALS is a progressive degenerative ... Their study has been published in the prestigious journal ...
... have long been appreciated, but now scientists at Duke ... makes mother,s milk better than infant formula in protecting ... in the August issue of the journal Current ... but not infant formula, fosters colonies of microbiotic flora ...
Cached Biology News:To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma 2To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma 3To cap or not to cap: Scientists find new RNA phenomenon that challenges dogma 4Zebra fish point the way towards new therapies for amyotrophic lateral sclerosis 2Breast milk promotes a different gut flora growth than infant formulas 2Breast milk promotes a different gut flora growth than infant formulas 3
...
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...
Biology Products: